Mereo BioPharma Group plc

Share Issue/Capital Change • Aug 9, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7160G

Mereo BioPharma Group plc

09 August 2016

9 August 2016

Notice of Results

Mereo BioPharma Group plc ("Mereo" or the "Company") (AIM:MPH), a UK-based specialty biopharmaceutical company, will announce its interim results for the six months ended 30 June 2016 on Friday, 16 September 2016.

Enquiries:

Mereo BioPharma Group plc	+44 (0)333 023 7319
Denise Scots-Knight, Chief Executive Officer
Richard Bungay, Chief Financial Officer & COO
Cantor Fitzgerald Europe (Nominated Adviser and Broker)	+44 (0)20 7894 7000
Phil Davies
Will Goode
Rick Thompson
Callum Butterfield
RBC Capital Markets (Joint Broker)	+44 (0)20 7653 4000
Paul Tomasic
Rupert Walford
Thomas Stockman
Laura White
FTI Consulting (Public Relations Adviser)	+44 (0)20 3727 1000
Ben Atwell
Simon Conway
Brett Pollard

About Mereo

Mereo is a UK-based biopharmaceutical company focused on the development of innovative medicines that aim to address unmet medical needs in rare and specialty disease areas and improve patient quality of life. The Company seeks to selectively acquire development-stage product candidates with demonstrated clinically meaningful data from large pharmaceutical companies and to rapidly progress these product candidates to subsequent value inflection points.

Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. The Company has the option to directly commercialise products, for example in orphan diseases, in addition to partnering or divesting its products.

Mereo's initial portfolio consists of three mid-late stage clinical assets that were acquired from Novartis in July 2015.  BPS-804 is being developed for the prevention of fractures resulting from osteogenesis imperfecta (brittle bone disease); BCT-197, is being developed to treat inflammation in patients with an acute exacerbation of chronic obstructive pulmonary disease; and BGS-649 is a once-weekly pill to restore normal testosterone levels in men with hypogonadal hypogonadism.

In H1 2016 the Company initiated a Phase 2 study with BCT-197 and a Phase 2b study with BGS-649. Mereo intends to commence a Phase 2b/3 study during H2 2016 for BPS-804. Additional product opportunities (from a range of large pharmaceutical companies) are under active evaluation.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORBUGDIDGGBGLC